36
Participants
Start Date
November 27, 2018
Primary Completion Date
September 27, 2021
Study Completion Date
September 27, 2021
PF-06936308
PF-06936308 components will be administered 4 times per cycle. A cycle is 4 months.
H Lee Moffitt Cancer Center & Research Institute Inc, Tampa
Tennessee Oncology, PLLC, Nashville
The Sarah Cannon Research Institute, Nashville
Norton Cancer Institute Downtown, Louisville
Norton Cancer Institute Pharmacy, Downtown Pharmacy, Louisville
Norton Hospital, Louisville
Horizon Oncology Research, LLC, Lafayette
InnerVision Advanced Medical Imaging, Lafayette
University of Chicago Comprehensive Cancer Center at Silver Cross Hospital, New Lenox
Orland Park - University of Chicago Center for Advanced Care, Orland Park
The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy, Chicago
University of Chicago Medical Center, Chicago
Barnes-Jewish Hospital, St Louis
Washington University Infusion Center Pharmacy, St Louis
Washington University School of Medicine, St Louis
Siteman Cancer Center - South County, St Louis
Siteman Cancer Center - West County, Creve Coeur
Siteman Cancer Center - St. Peters, City of Saint Peters
The University of Kansas Cancer Center, Investigational Drug Services, Fairway
The University of Kansas Clinical Research Center, Fairway
The University of Kansas Cancer Center, Westwood
University of Utah, Huntsman Cancer Hospital, Salt Lake City
University of Utah, Huntsman Cancer Institute, Salt Lake City
Ronald Reagan UCLA Medical Center, Los Angeles
UCLA Hematology/Oncology, Los Angeles
UCLA Hematology/Oncology - Parkside, Santa Monica
UCLA Hematology/Oncology - Santa Monica, Santa Monica
UCSD Medical Center - Encinitas, Encinitas
UC San Diego Medical Center - La Jolla (Jacobs Medical Center / Thornton Hospital), La Jolla
UC San Diego Perlman Medical Offices, La Jolla
UCSD Medical Center - Vista, Vista
UC San Diego Moores Cancer Center, La Jolla
UC San Diego Medical Center - Hillcrest, San Diego
University of Washington Medical Center - Translational Research Unit (TRU), Seattle
Lead Sponsor
Pfizer
INDUSTRY